Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News ViaDerma Inc (EM) VDRM

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
ViaDerma, Inc., through its subsidiary, manufactures and sells pharmaceutical related products in the United States. The company’s lead product is Vitastem, a tetracycline and topical delivery technology for antibiotics to pain relief, skincare, and other. It is also developing various products for vitiligo, psoriasis, eczema, and other skin conditions using SkinPass topical delivery system, as... see more

Recent & Breaking News (EXPM:VDRM)

ViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market Changes

GlobeNewswire July 16, 2025

ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory Compliance

GlobeNewswire June 4, 2025

ViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in India

GlobeNewswire January 21, 2025

ViaDerma Announces Significant 2024 Achievements and International Expansion

GlobeNewswire December 10, 2024

ViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow Growth

GlobeNewswire October 3, 2024

ViaDerma Completes First Shipment of 500,000 Units to Nigeria

GlobeNewswire September 10, 2024

ViaDerma Announces Shipment of 500,000 Units of its Flagship Product to Nigeria

GlobeNewswire August 13, 2024

ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires

GlobeNewswire August 1, 2024

ViaDerma Provides Highlights of Quarterly Financial Report

GlobeNewswire June 6, 2024

ViaDerma Update on Stability Testing, Global Sales Distribution, National Licensing, Nupelo & More

GlobeNewswire October 24, 2023

ViaDerma Announces Updates for Vitastem Global Sales Expansion, Nupelo FDA-Registration Status & More 

GlobeNewswire July 6, 2023

ViaDerma Announces FDA Registration Application Update & Brand Name for New Hair Regrowth Product

GlobeNewswire March 16, 2023

ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product

GlobeNewswire March 8, 2023

ViaDerma Provides an Update on Current & Future Business Activities

GlobeNewswire March 2, 2023

ViaDerma Engages Intent Sciences to Power Up Digital Marketing & Brand Development

GlobeNewswire January 12, 2023

ViaDerma Successfully Completes Quality Control Testing of its New Vitastem Products

GlobeNewswire September 15, 2022

ViaDerma Announces the Implementation of Internal Quality Control Measures for its New Vitastem Products

GlobeNewswire June 22, 2022

ViaDerma's 2021 Annual Report Shows Strong Revenue Growth Over the Previous Year

GlobeNewswire March 31, 2022

ViaDerma, Inc. Set to Launch Two New and Improved Versions of its Flagship Product, Vitastem and Vitastem Ultra

GlobeNewswire October 4, 2021

ViaDerma, Inc. Files Amended Financial Statements

GlobeNewswire August 24, 2021

Podcasts